Missouri: A US judge has approved a $7.25 billion settlement proposed by German pharmaceutical and biotechnology company Bayer to resolve thousands of lawsuits alleging that its weedkiller Roundup causes cancer.
Missouri Judge Timothy Boyer approved the nationwide settlement, describing it as ‘fair, reasonable, and adequate’. The agreement aims to bring an end to years of legal disputes involving claims that exposure to Roundup caused non-Hodgkin lymphoma.
Under the settlement, compensation will be provided to eligible Roundup users who have already been diagnosed with non-Hodgkin lymphoma, as well as those who develop the disease in the future. Individual payouts are expected to range from $10,000 to $165,000, depending on factors including the frequency of product use, the timing of diagnosis and the severity of the illness.
Bayer will contribute annual payments to a dedicated settlement fund over a period of up to 21 years, with the total amount reaching as much as $7.25 billion. Although some attorneys raised objections, arguing that the proposed compensation was insufficient, Judge Boyer said he did not want to further delay payments to people affected by the claims.
The settlement adds to the approximately $10 billion Bayer has already paid to resolve previous Roundup-related litigation. The company maintains that Roundup does not cause cancer and continues to dispute allegations concerning the safety of its weedkiller.

The latest agreement follows a significant legal development in June, when the US Supreme Court ruled in Bayer’s favour, overturning a $1.25 million award to a Missouri man who claimed that Roundup and its active ingredient, glyphosate, caused his non-Hodgkin lymphoma. In a 7-2 decision, the court ruled that Bayer could not be held liable under state failure-to-warn claims because federal regulations do not require a cancer warning on the product’s label.
Originally developed by Monsanto in the 1970s, Roundup became one of the world’s most widely used herbicides. Its active ingredient, glyphosate, was classified as a probable human carcinogen by the International Agency for Research on Cancer, part of the World Health Organisation, in 2015. However, Bayer, the US Environmental Protection Agency and several other regulatory authorities have disputed the cancer-related findings. The conflicting assessments have kept glyphosate at the centre of an ongoing scientific and legal debate.
Since acquiring Monsanto in 2018, Bayer has faced thousands of lawsuits across US state and federal courts, with several juries awarding substantial damages to individuals who claimed that prolonged exposure to Roundup contributed to their cancer diagnoses. The latest settlement represents another major attempt by the company to address the long-running litigation and limit its financial exposure.

